Marrone Bio Innovations (NASDAQ:MBII) received a $4.00 price objective from equities research analysts at HC Wainwright in a report issued on Thursday. The brokerage presently has a “buy” rating on the basic materials company’s stock. HC Wainwright’s price target suggests a potential upside of 270.37% from the stock’s previous close.
Separately, ValuEngine lowered Marrone Bio Innovations from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $2.50.
Marrone Bio Innovations (MBII) opened at $1.08 on Thursday. The company has a quick ratio of 0.36, a current ratio of 0.69 and a debt-to-equity ratio of -1.14. Marrone Bio Innovations has a 12-month low of $0.85 and a 12-month high of $2.45.
Marrone Bio Innovations Company Profile
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.